Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced an investor call on March 1, 2022, at 8:00 AM EST to discuss its 2021 financial results and provide a corporate update. Interested participants can join via phone or a webcast. A replay will be available on the company's website. Pieris specializes in developing novel biotherapeutics, including inhalable Anticalin proteins for respiratory diseases and immuno-oncology treatments, supported by their proprietary technology platform.

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update.

To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.

For those unable to participate in the conference call or listen to the webcast, a replay will be available on the Investors section of the Company's website, www.pieris.com.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Forward Looking Statements:

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the expected timing and potential outcomes of the reporting by the Company of key clinical data from its programs, references to novel technologies and methods and our business and product development plans, including the Company's cash resources, the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data, making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, cinrebafusp alfa, PRS-344, and PRS-352 and the expected timing of the initiation of the next stage of cinrebafusp alfa's development in gastric cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the U.S. Food and Drug Administration; competition in the industry in which we operate; delays or disruptions due to COVID-19; and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and the Company's Quarterly Reports on Form 10-Q.

Investor Relations Contact:
Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/689964/Pieris-Pharmaceuticals-To-Host-Full-Year-2021-Investor-Call-and-Provide-Corporate-Update-on-March-1-2022

FAQ

When is Pieris Pharmaceuticals' investor call scheduled?

The investor call for Pieris Pharmaceuticals is scheduled for March 1, 2022, at 8:00 AM EST.

How can I access the Pieris Pharmaceuticals investor call?

You can access the Pieris Pharmaceuticals investor call by dialing 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International). A webcast is also available online.

What will Pieris Pharmaceuticals discuss during the investor call?

During the investor call, Pieris Pharmaceuticals will discuss their financial results for 2021 and provide a corporate update.

Where can I find the replay of the Pieris Pharmaceuticals investor call?

The replay of the Pieris Pharmaceuticals investor call will be available on the Investors section of their website.

What is Pieris Pharmaceuticals known for?

Pieris Pharmaceuticals is known for developing novel biotherapeutics using their proprietary Anticalin technology platform for respiratory diseases and cancer.